兔停用曲伏前列素后角膜硬度恢复的研究
研究将72只兔随机分为用药组、停药组和空白组,右眼给予曲伏前列素12周,停药组再观察12周。结果显示用药组中央角膜厚度和切线模量降低、基质纤维间距增大,停药后这些变化部分逆转;作者认为曲伏前列素可能抑制角膜生长,儿童青少年使用需谨慎考虑,并可能低估眼压测量值。
要点
- 曲伏前列素用药12周使兔中央角膜厚度降低(P < 0.05)。
- 停药12周后中央角膜厚度回升但仍低于空白对照组(P < 0.05)。
- 用药组切线模量在平均组织应力2、4、6 kPa时显著低于对照眼(P < 0.05),停药后恢复。
核心结论
- 曲伏前列素治疗似乎使角膜组织软化、降低组织厚度并通过增加纤维间距降低基质胶原纤维密度,这些变化在停药后部分逆转。
- 作者认为曲伏前列素可能进一步抑制角膜生长,因此儿童和青少年使用时应仔细考虑。
- 作者指出曲伏前列素降低角膜硬度的效应可能导致眼压测量值被低估,从而高估降眼压治疗效果。
研究设计与样本
- 研究将72只兔随机分为用药组(M)、停药组(MW)和空白组(B)。
- 用药组和停药组右眼(MT和MWT)接受曲伏前列素治疗12周,随后用药组处死,停药组再停药观察12周。
- 用药组和停药组对侧眼(MC和MWC)不治疗;空白对照组(BC)整个24周不治疗。
- 每组18只兔的角膜在充气条件下进行力学测试以估算切线模量(Et),其余6只兔的角膜进行电子显微镜分析纤维直径和纤维间距。
主要发现
- 用药眼(MT和MWT组)中央角膜厚度在曲伏前列素治疗12周后降低(P < 0.05)。
- MWT组停药12周后中央角膜厚度增加但仍低于BC组(P < 0.05)。
- MT组切线模量在平均组织应力2、4、6 kPa时显著低于MC组(P < 0.05);MWT、MWC和BC组间切线模量无显著差异。
- MT组基质纤维间距显著大于MC组(P < 0.05),停药后MWT、MWC和BC组间无差异。
- 所有组间胶原纤维平均直径无显著差异(均P > 0.05)。
临床怎么用
- 作者认为曲伏前列素可能抑制角膜生长,儿童和青少年使用时应仔细考虑。
- 作者指出曲伏前列素降低角膜硬度的效应可能导致眼压测量值被低估,从而高估降眼压治疗效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate if the effect of travoprost on corneal material stiffness could be restored after drug withdrawal. METHODS: Seventy-two rabbits were randomly allocated into three groups: medicine (M), medicine withdrawal (MW), and blank (B). Within the M and MW groups, treatment with travoprost was administered to the right eyes (MT and MWT) over a period of 12 weeks. Subsequently, the M group was killed, but the MW group underwent an additional 12-week period for treatment withdrawal. No treatment was given to the contralateral eyes (MC and MWC) in the M and MW groups. A separate blank control (BC) group remained untreated for the entire 24-week duration. In each group, corneas from 18 rabbits were tested mechanically under inflation conditions to estimate their tangent modulus (Et). The corneas of the remaining six rabbits underwent electron microscopy analysis, which focused on fibril diameter and interfibrillar spacing. RESULTS: Central corneal thickness (CCT) of the treated eyes (MT and MWT groups) decreased with 12 weeks of travoprost treatment (P < 0.05). The CCT in the MWT group increased after 12 weeks of withdrawal but was still lower than that in the BC group (P < 0.05). The Et of the MT group was significantly lower than that of the MC group at mean tissue stresses of 2, 4, and 6 kPa (P < 0.05). Conversely, no significant difference in Et values was observed between the MWT, MWC, and BC groups, indicating recovery after treatment cessation. Furthermore, the stromal interfibrillar spacing of the treated MT group was significantly larger (P < 0.05) than that of the control MC group, but no disparity was noted among the MWT, MWC, and BC groups following treatment withdrawal. Additionally, there were no significant differences in the mean diameter of collagen fibrils among all groups (all P > 0.05). CONCLUSIONS: Travoprost treatment appears to soften corneal tissue, decrease tissue thickness, and reduce the density of stromal collagen fibers by increasing the interfibrillar spacing. These changes were partially reversed after treatment cessation. Travoprost could further inhibit corneal growth, so its use in childhood and adolescence should be carefully considered. Additionally, the effect of travoprost in reducing corneal stiffness may lead to underestimations of intraocular pressure (IOP) measurement and hence overestimations in the effect of treatment in lowering IOP.
引用
- Zheng X, Wang C, Fan Y, et al. Restoration of Corneal Stiffness in Rabbits Following Withdrawal of Travoprost. Invest Ophthalmol Vis Sci. 2024. PMID: 39546291. doi:10.1167/iovs.65.13.35
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。